LP-284
High-grade B-cell lymphomas, Soft Tissue Sarcoma, other DDR-deficient cancers
Phase 1Active (Orphan Designation for Sarcoma)
Key Facts
Indication
High-grade B-cell lymphomas, Soft Tissue Sarcoma, other DDR-deficient cancers
Phase
Phase 1
Status
Active (Orphan Designation for Sarcoma)
Company
About Lantern Pharma
Lantern Pharma is an AI-driven oncology company using its RADR® platform to streamline drug discovery and clinical development. The company has advanced a pipeline to Phase 2, focusing on biomarker-stratified patient populations to improve success rates and reduce costs. Its strategy centers on leveraging massive datasets and machine learning to reposition drug candidates and design more efficient clinical trials. Key achievements include building a significant data asset, advancing multiple programs into the clinic, and securing orphan drug designations.
View full company profile